omniture
TAIGEN BIOTECHNOLOGY

Latest News

HEC TaiGen Initiates Phase III Trial of Combination of Furaprevir and Yimitasvir for the Treatment of Chronic Hepatitis C Patients in China

TAIPEI, , April 23, 2019 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced...

2019-04-23 15:58 589

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration

TAIPEI, , May 30, 2017 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today annou...

2017-05-30 13:15 1600

TaiGen Biotechnology and HEC Pharmaceutical Executed Equity Purchase Agreement for Their HCV Joint Venture

TAIPEI, , March 27, 2017 /PRNewswire/ -- TaiGen Biotechnology Co., Ltd. ("TaiGen") announced today t...

2017-03-27 17:24 1075

TaiGen Biotechnology To Establish a New Company With HEC Pharmaceutical in China for Treatment of Chronic Hepatitis C

TAIPEI, , Oct. 30, 2016 /PRNewswire/ -- TaiGen Biotechnology Co., Ltd. ("TaiGen") announced today th...

2016-10-30 20:18 1434

TaiGen Biotechnology Out-Licenses Taigexyn(R) (Nemonoxacin) to Productos Científicos for the Latin American Market

TAIPEI, , Aug. 25, 2016 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today annou...

2016-08-25 17:49 1571

TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn(R) (nemonoxacin)

TAIPEI, , June 13, 2016 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced t...

2016-06-13 23:30 1517

TaiGen Biotechnology Launches Taigexyn(R) in Taiwan

TAIPEI, , Dec. 15, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today annou...

2015-12-16 11:02 1983

TaiGen's Intravenous Taigexyn(R) Successfully Achieved Primary Endpoint in Phase 3 Clinical Trial for Community Acquired Pneumonia

TAIPEI, , Dec. 3, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") made a publi...

2015-12-03 19:04 1739

TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial in Acute Myeloid Leukemia in China

TAIPEI, April 30, 2015 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announ...

2015-04-30 13:17 1273

TaiGen Biotechnology Receives Marketing Approval from the Taiwan Food and Drug Administration for Taigexyn(R) (nemonoxacin) in Taiwan

TAIPEI, March 13, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announ...

2014-03-13 17:22 884

TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R))

TAIPEI, Jan. 15, 2014 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announc...

2014-01-15 15:00 1153

TaiGen Biotechnology Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Nemonoxacin (Taigexyn(R))

TAIPEI, Dec. 23, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announc...

2013-12-23 15:00 846

TaiGen Biotechnology Reports Phase IIa Data for TG-0054 at the 2013 American Society of Hematology (ASH) Annual Meeting

TAIPEI, Oct. 29, 2013 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced the...

2013-10-30 09:46 957

TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhej...

2012-06-25 14:00 1188

TaiGen Biotechnology Obtains the Worldwide Rights for Nemonoxacin

TAIPEI, Dec. 9, 2011 /PRNewswire-Asia/ -- TaiGen Biotechnology ("TaiGen") announced today that Warne...

2011-12-09 15:48 791

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic

TAIPEI, Oct. 14 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. today announced that TaiGen has ...

2010-10-14 21:00 930